Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. - Wikidata - awgldk - TriplyDB

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.

http://www.wikidata.org/entity/Q41923154

about

Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study.Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt's hepatocellular cancer epidemic: simulation of alternatives.Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.IL-1α correlates with severity of hepatitis C virus-related liver diseases.Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications

P2860

Q45323682-AFF49E7C-ECDB-4126-92C8-C9CE6E8D9BAD Q53688288-7A2054D2-E2B3-4A1B-9621-DD3059AC090E Q53837635-6FEAFF27-F8B2-47FE-9C6A-858CA064943B Q54239807-C161AFD9-1DC7-4E83-9D6F-DC8ECBBED5E8 Q54964642-0430EBFD-FBCB-4D64-8E2B-175B725A143B Q55717409-9224A500-D425-49A5-9235-D5082E38DA30 Q57815114-38BD512D-1472-4AE6-9850-A0BCB9EEFB9E Q58765012-27A36D05-476C-44BF-B1EC-14DC816295F2

P2860

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.

http://www.wikidata.org/entity/Q41923154

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Efficacy and safety of sofosbu ...... n real-life clinical practice.

@en

type

label

Efficacy and safety of sofosbu ...... n real-life clinical practice.

@en

prefLabel

Efficacy and safety of sofosbu ...... n real-life clinical practice.

@en

P1433

Q41923154-5C45208E-E8EE-4D56-AF8E-28969A5F8AB3

P1476

Q41923154-D8FAEFFE-5BFC-415E-A743-8CA9762BCC23

P2093

Q41923154-DD7D1AF1-622B-4D3B-8D4A-E350C5FCB518

Q41923154-E377C8B1-3FA3-4F7C-AC50-93CAD760DE35

Q41923154-FA5ED514-304E-4561-8C08-FDB558203943

P2860

Q41923154-05D10034-9236-43B2-9E40-54A1691AB924

Q41923154-0E7BFE2A-2B8C-4B74-80DC-EB718C1AFB07

Q41923154-1E94F456-803B-41EE-A8D8-39272BDB6D54

Q41923154-2BCD2BAC-763C-4BB8-8341-8E139091D591

Q41923154-3721096E-810A-4898-A8C7-B34A4E4446AF

Q41923154-4C6FEAD4-D448-48AB-9781-AA5ACF7A2280

Q41923154-4D358826-6E4C-42AB-8821-D30044507D62

Q41923154-59C6C108-A63A-454B-BDDB-5AF04FFEF01A

Q41923154-61F45C31-4B46-4D74-9DAB-68FE878ABD26

Q41923154-6E664841-4B55-4D6A-A6C1-5A90DE329209

P2888

Q41923154-2EB76250-6042-4CE5-B51C-43A30C7AE7C5

P304

Q41923154-233F258E-6699-46BE-BDDD-E6F185CFD6FC

P31

Q41923154-4686581C-D112-447F-8197-BD5F5894B8DF

P356

Q41923154-0E42602D-2D86-4430-88B8-820D7EE525C7

P433

Q41923154-723CFCA5-2A34-4F6F-951E-EF40E241B1B8

P478

Q41923154-7E2F4660-50F2-4641-A202-6E82B02D67CB

P50

Q41923154-15B83397-FBCD-49C9-9B25-22F51B0002B6

Q41923154-347B0E8F-757B-4788-BC9C-022166648E63

Q41923154-B865984A-0DF9-48F3-ACA0-F52DCD57F4D4

P577

Q41923154-86E3ABF2-11B2-49A8-A30E-B1BBF4B84A2A

P698

Q41923154-A343801F-9BB5-4F3E-A014-478A569670E3

P921

Q41923154-57D33982-C0D1-4598-A6E6-0FFF92582EDE

Q41923154-8981BE11-1584-4B7B-AC44-3D74F2A0CA86

P356

S00705-017-3573-0

P1433

Archives of Virology

P1476

Efficacy and safety of sofosbu ...... in real-life clinical practice

@en

P2093

Mohamed Sharaf-Eldin

http://www.w3.org/2001/XMLSchema#string

Rehab Badawi

http://www.w3.org/2001/XMLSchema#string

Youssef K Ahmad

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology and genotype distribution of the hepatitis C virus infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Future treatment of patients with HCV cirrhosis.

Improving outcome in patients with hepatitis C virus genotype 4.

Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?

Hepatitis C genotype 4: What we know and what we don't yet know.

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

P2888

s00705-017-3573-0

P304

51-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00705-017-3573-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P50

Shaimaa Soliman

Sherief Abd-Elsalam

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28983675

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis